Elliott Advisors (UK) Limited
Elliott only willing to support domination agreement for STADA Arzneimittel AG at a minimum compensation of EUR 74.40
London (31st August, 2017) – Elliott Associates, L.P. and Elliott International, L.P. together with affiliated entities (“Elliott”) has informed Nidda Healthcare Holding AG that Elliott will only support a profit and loss transfer and/or domination agreement between STADA Arzneimittel AG and Nidda Healthcare Holding AG or any of its subsidiaries with all their current and future shares held in STADA Arzneimittel AG if the compensation for minority shareholders pursuant to section 305 para 1 of the German Stock Corporation Act set forth in the published resolution proposal regarding such agreement amounts to not less than EUR 74.40 per share.
About Elliott Elliott Management Corporation was founded in 1977 and has one of the longest track records of any private investment fund manager operating today. Employing a multi-strategy trading approach, the firm manages approximately USD 33 billion in two funds for a range of investors, including pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Elliott Management, which is headquartered in New York, has approximately 400 employees worldwide, with offices in the U.S., London, Hong Kong and Tokyo. The firm’s principal objective is to generate a return which is as high as is consistent with a goal of minimizing losses during adverse financial market periods. ### Media Contact: Charles Barker Corporate Communications Thomas Katzensteiner / Tobias Eberle +49 69 79 40 90 25 +49 69 79 40 90 24 Thomas.Katzensteiner@charlesbarker.de Tobias.Eberle@charlesbarker.de End of Media Release Issuer: Elliott Advisors (UK) Limited Key word(s): Finance
31.08.2017 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG. |
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found